Find a Physician

Return to Pulmonary Hypertension Comprehensive Care Center Overview

More on Pulmonary Hypertension Comprehensive Care Center

Health Information

Return to Pulmonary Hypertension Comprehensive Care Center Overview

More on Pulmonary Hypertension Comprehensive Care Center

Research and Clinical Trials

Return to Pulmonary Hypertension Comprehensive Care Center Overview

More on Pulmonary Hypertension Comprehensive Care Center

For Patients, Families & Visitors

Return to Pulmonary Hypertension Comprehensive Care Center Overview

More on Pulmonary Hypertension Comprehensive Care Center

Professionals

Return to Pulmonary Hypertension Comprehensive Care Center Overview

More on Pulmonary Hypertension Comprehensive Care Center

Hospital News

Return to Pulmonary Hypertension Comprehensive Care Center Overview

More on Pulmonary Hypertension Comprehensive Care Center

Cardiology

Pulmonary Hypertension Comprehensive Care Center

Erika Berman Rosenzweig, MD, Director

The Pulmonary Hypertension Center at NewYork-Presbyterian/Morgan Stanley Children's Hospital is one of the largest in the world. Established over 20 years ago, the Center is committed to the treatment of both adults and children with pulmonary hypertension, a serious condition which can occur at any age and affects the smallest blood vessels in the lungs. Left untreated, it can lead to right heart failure.

Who do we treat?

At the Center, we treat idiopathic (primary) pulmonary hypertension and pulmonary hypertension associated with a variety of conditions, including:

  • Congenital heart disease
  • Genetic (familial) conditions
  • Scleroderma
  • Lupus
  • Clotting disorders
  • Pulmonary hypertension in newborns
  • Chronic lung disease
  • HIV disease
  • Sickle cell disease
  • Toxins

Our research efforts

Our team members remain on the forefront of research to advance the field. In fact, our Center has participated in most of the pivotal clinical trials to date for the development of new medical treatments for pulmonary hypertension, including the first drug approved for treatment of this condition in 1995.

Today, new therapies -- including prostanoids (epoprostenol, treprostinil, iloprost), endothelin receptor antagonists (ambrisentan, bosentan), and phosphodiesterase 5-inhibitors (sildenafil) -- have dramatically improved quality of life and long-term outcome for patients living with pulmonary hypertension. Our research team is currently participating in several clinical trials of novel medications to treat pulmonary arterial hypertension.

Is education provided?

Education of patients and their families is also a high priority. Our staff of doctors and nurses is readily available to educate and support our patients and their families.

Patients and their families who are facing this challenging condition can be assured of receiving state-of-the-art care at the Pulmonary Hypertension Center. We remain committed to our ultimate goal: finding a cure for pulmonary arterial hypertension.

Pulmonary Hypertension Team

Erika Berman Rosenzweig, MD, Director
Usha Krishnan, MD, Associate Director -- Pediatric
Diane Kerstein, MD
Warren Zuckerman, MD
Daniela Brady, RN
Jane Devereaux, RN
Candy Yanes, RN
Melida Burgos, Administrative Assistant

Contact

Pulmonary Hypertension Comprehensive Care Center
NewYork-Presbyterian/Morgan Stanley Children’s Hospital
3959 Broadway
New York, NY 10032
Clinical Staff: (212) 305-4436
Office Fax: (212) 342-1443

Contact

Cardiology
Directions
Clinical Staff: (212) 305-8509
  • Bookmark
  • Print




Top of page